Literature DB >> 23669245

Wasting mechanisms in muscular dystrophy.

Jonghyun Shin1, Marjan M Tajrishi, Yuji Ogura, Ashok Kumar.   

Abstract

Muscular dystrophy is a group of more than 30 different clinical genetic disorders that are characterized by progressive skeletal muscle wasting and degeneration. Primary deficiency of specific extracellular matrix, sarcoplasmic, cytoskeletal, or nuclear membrane protein results in several secondary changes such as sarcolemmal instability, calcium influx, fiber necrosis, oxidative stress, inflammatory response, breakdown of extracellular matrix, and eventually fibrosis which leads to loss of ambulance and cardiac and respiratory failure. A number of molecular processes have now been identified which hasten disease progression in human patients and animal models of muscular dystrophy. Accumulating evidence further suggests that aberrant activation of several signaling pathways aggravate pathological cascades in dystrophic muscle. Although replacement of defective gene with wild-type is paramount to cure, management of secondary pathological changes has enormous potential to improving the quality of life and extending lifespan of muscular dystrophy patients. In this article, we have reviewed major cellular and molecular mechanisms leading to muscle wasting in muscular dystrophy. This article is part of a Directed Issue entitled: Molecular basis of muscle wasting.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CMD; DGC; DMD; Duchenne muscular dystrophy; ECM; IKK; LGMD; MAPK; MMPs; Matrix metalloproteinases; MuRF1; Muscular dystrophy; NF-kappa B; NF-κB; NF-κB-inducing kinase; NIK; NO; Osteopontin; RNS; ROS; TGF-β; TRPC; congenital muscular dystrophy; dystrophin glycoprotein complex; extracellular matrix; inhibitor of I kappa B kinase α; limb-girdle muscular dystrophy; matrix metalloproteinases; mitogen-activated protein kinase; muscle RING-finger protein-1; nitric oxide; nuclear factor-kappa B; reactive nitrogen species; reactive oxygen species; transforming growth factor-β; transient receptor potential canonical

Mesh:

Substances:

Year:  2013        PMID: 23669245      PMCID: PMC3759654          DOI: 10.1016/j.biocel.2013.05.001

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  212 in total

1.  Uncontrolled calcium sparks act as a dystrophic signal for mammalian skeletal muscle.

Authors:  Xu Wang; Noah Weisleder; Claude Collet; Jingsong Zhou; Yi Chu; Yutaka Hirata; Xiaoli Zhao; Zui Pan; Marco Brotto; Heping Cheng; Jianjie Ma
Journal:  Nat Cell Biol       Date:  2005-04-17       Impact factor: 28.824

Review 2.  Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases.

Authors:  Jialiang Hu; Philippe E Van den Steen; Qing-Xiang A Sang; Ghislain Opdenakker
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694

3.  Oxidative damage to muscle protein in Duchenne muscular dystrophy.

Authors:  J W Haycock; S MacNeil; P Jones; J B Harris; D Mantle
Journal:  Neuroreport       Date:  1996-12-20       Impact factor: 1.837

4.  Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential.

Authors:  T Turpeenniemi-Hujanen; U P Thorgeirsson; I R Hart; S S Grant; L A Liotta
Journal:  J Natl Cancer Inst       Date:  1985-07       Impact factor: 13.506

5.  Elevated levels of active matrix metalloproteinase-9 cause hypertrophy in skeletal muscle of normal and dystrophin-deficient mdx mice.

Authors:  Saurabh Dahiya; Shephali Bhatnagar; Sajedah M Hindi; Chunhui Jiang; Pradyut K Paul; Shihuan Kuang; Ashok Kumar
Journal:  Hum Mol Genet       Date:  2011-08-16       Impact factor: 6.150

6.  Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy.

Authors:  Mahasweta Girgenrath; Mary Lou Beermann; Vivek K Vishnudas; Sachiko Homma; Jeffrey Boone Miller
Journal:  Ann Neurol       Date:  2009-01       Impact factor: 10.422

Review 7.  Targeting the TGFβ signalling pathway in disease.

Authors:  Rosemary J Akhurst; Akiko Hata
Journal:  Nat Rev Drug Discov       Date:  2012-09-24       Impact factor: 84.694

8.  Evidence of oxidative stress in mdx mouse muscle: studies of the pre-necrotic state.

Authors:  M H Disatnik; J Dhawan; Y Yu; M F Beal; M M Whirl; A A Franco; T A Rando
Journal:  J Neurol Sci       Date:  1998-11-26       Impact factor: 3.181

9.  Myotubes from transgenic mdx mice expressing full-length dystrophin show normal calcium regulation.

Authors:  W F Denetclaw; F W Hopf; G A Cox; J S Chamberlain; R A Steinhardt
Journal:  Mol Biol Cell       Date:  1994-10       Impact factor: 4.138

10.  Autophagy is defective in collagen VI muscular dystrophies, and its reactivation rescues myofiber degeneration.

Authors:  Paolo Grumati; Luisa Coletto; Patrizia Sabatelli; Matilde Cescon; Alessia Angelin; Enrico Bertaggia; Bert Blaauw; Anna Urciuolo; Tania Tiepolo; Luciano Merlini; Nadir M Maraldi; Paolo Bernardi; Marco Sandri; Paolo Bonaldo
Journal:  Nat Med       Date:  2010-10-31       Impact factor: 53.440

View more
  58 in total

1.  What Can be Learned from the Time Course of Changes in Low-Frequency Stimulated Muscle?

Authors:  Dirk Pette
Journal:  Eur J Transl Myol       Date:  2017-06-24

Review 2.  Wnt signaling in skeletal muscle dynamics: myogenesis, neuromuscular synapse and fibrosis.

Authors:  Pedro Cisternas; Juan P Henriquez; Enrique Brandan; Nibaldo C Inestrosa
Journal:  Mol Neurobiol       Date:  2013-09-07       Impact factor: 5.590

3.  Proteomic profiling of the dystrophin complex and membrane fraction from dystrophic mdx muscle reveals decreases in the cytolinker desmoglein and increases in the extracellular matrix stabilizers biglycan and fibronectin.

Authors:  Sandra Murphy; Heinrich Brinkmeier; Mirjam Krautwald; Michael Henry; Paula Meleady; Kay Ohlendieck
Journal:  J Muscle Res Cell Motil       Date:  2017-08-12       Impact factor: 2.698

Review 4.  The TWEAK-Fn14 pathway: a potent regulator of skeletal muscle biology in health and disease.

Authors:  Marjan M Tajrishi; Timothy S Zheng; Linda C Burkly; Ashok Kumar
Journal:  Cytokine Growth Factor Rev       Date:  2013-12-24       Impact factor: 7.638

Review 5.  ER stress in skeletal muscle remodeling and myopathies.

Authors:  Dil Afroze; Ashok Kumar
Journal:  FEBS J       Date:  2017-12-29       Impact factor: 5.542

6.  Reliability, validity and description of timed performance of the Jebsen-Taylor Test in patients with muscular dystrophies.

Authors:  Mariana Cunha Artilheiro; Francis Meire Fávero; Fátima Aparecida Caromano; Acary de Souza Bulle Oliveira; Nelson Carvas; Mariana Callil Voos; Cristina Dos Santos Cardoso de Sá
Journal:  Braz J Phys Ther       Date:  2017-12-08       Impact factor: 3.377

Review 7.  Stem cell-based therapies for Duchenne muscular dystrophy.

Authors:  Congshan Sun; Carlo Serra; Gabsang Lee; Kathryn R Wagner
Journal:  Exp Neurol       Date:  2019-10-19       Impact factor: 5.330

Review 8.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

9.  Toll-like receptor signalling in regenerative myogenesis: friend and foe.

Authors:  Sajedah M Hindi; Ashok Kumar
Journal:  J Pathol       Date:  2016-04-12       Impact factor: 7.996

10.  Fyn Activation of mTORC1 Stimulates the IRE1α-JNK Pathway, Leading to Cell Death.

Authors:  Yichen Wang; Eijiro Yamada; Haihong Zong; Jeffrey E Pessin
Journal:  J Biol Chem       Date:  2015-08-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.